Page last updated: 2024-12-08

desmethylnaproxen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

desmethylnaproxen: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

desmethylnaproxen : A member of the class of naphthols that is naproxen in which the 6-methoxy group has been demethylated. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID162920
SCHEMBL ID554068
MeSH IDM0106142

Synonyms (18)

Synonym
desmethylnaproxen
2-(6-hydroxynaphthalen-2-yl)propanoic acid
FT-0666191
FT-0666192
60756-73-2
2-naphthaleneacetic acid, 6-hydroxy-alpha-methyl-
AKOS023801034
SCHEMBL554068
racemic 6-hydroxy-alpha-methyl-2-naphthalene acetic acid
6-hydroxy-alpha-methyl-2-naphthaleneacetic acid
2-(6-hydroxynaphthalen-2-yl)propionic acid
2-(6-hydroxy-naphthalen-2-yl)-propionic acid
2-(6-hydroxynaphthalen-2-yl)-propionic acid
XWJUDDGELKXYNO-UHFFFAOYSA-N
racemic 6-hydroxy-alpha-methyl-2-naphthaleneacetic acid
6-hydroxy-2-naphthyl-alpha-methylacetic acid
FT-0666193
DTXSID801016131

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" •Prolonged exposure of nontargeted organisms to naproxen can cause adverse effects."( Naproxen in the environment: its occurrence, toxicity to nontarget organisms and biodegradation.
Guzik, U; Wojcieszyńska, D, 2020
)
0.56

Pharmacokinetics

Both naproxen and 6-O-desmethylnaproxen in saliva samples can be effectively quantified using LC-MS/MS. This methodology proved to be rapid, sensitive, accurate and selective for each drug and allows for the analysis of their pharmacokinetic parameters.

ExcerptReferenceRelevance
" The mean elimination half-life of naproxen was 24."( The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine.
Guelen, PJ; Van Den Biggelaar-Martea, M; Verwey-Van Wissen, CP; Vree, ML; Vree, TB, 1993
)
0.54
" To further understand the absorption, distribution, and metabolism of this drug alone and in combination with esomeprazole, we will analyze the pharmacokinetic parameters of naproxen and its major metabolite, 6-O-desmethylnaproxen, in saliva samples."( Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography-tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazole.
Calvo, AM; Dionísio, TJ; Faria, FC; Morettin, M; Oliveira, GM; Santos, CF, 2020
)
1.01
" Both naproxen and 6-O-desmethylnaproxen in saliva samples can be effectively quantified using LC-MS/MS, this methodology proved to be rapid, sensitive, accurate and selective for each drug and allows for the analysis of their pharmacokinetic parameters, in both situations."( Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography-tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazol-Results.
Calvo, AM; Dionísio, TJ; Faria, FAC; Oliveira, GM; Polanco, NLDH; Santos, CF; Siqueira-Sandrin, VS, 2022
)
1.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (14.81)18.7374
1990's8 (29.63)18.2507
2000's5 (18.52)29.6817
2010's7 (25.93)24.3611
2020's3 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.25 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.45%)5.53%
Reviews1 (3.45%)6.00%
Case Studies1 (3.45%)4.05%
Observational0 (0.00%)0.25%
Other26 (89.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]